Dr. Susan Panullo on Optune Versus Salvage Chemotherapy in Glioblastoma

Susan Panullo, MD, director, Neuro-oncology, director, Neurosurgical Radiosurgery, Weill Cornell Brain and Spine Center, discusses the improvement in quality of life in patients with glioblastoma treated with Optune (NovoTTF-100A).

Susan Panullo, MD, director, Neuro-oncology, director, Neurosurgical Radiosurgery, Weill Cornell Brain and Spine Center, discusses the improvement in quality of life in patients with glioblastoma treated with Optune (NovoTTF-100A). Panullo says patients treated with Optune versus patients treated with salvage chemotherapy both lived the same amount of time, with the former's quality of life being much better than the latter's.